Safety of hormonal treatments in women with genitourinary syndrome of menopause and a history of breast cancer: systematic review and meta-analysis
DOI:
https://doi.org/10.59464/2359-4632.2025.3750Keywords:
Genitourinary Syndrome of Menopause, Breast Cancer, Estrogen therapyAbstract
Objective: To analyze the use of hormonal therapy in women with genitourinary syndrome of menopause (GSM) and a history of breast cancer. Methods: This is a systematic review conducted in April 2025, including observational studies and clinical trials published between 2019 and 2024 in the PubMed, Scopus, SciELO, and BVS databases. Studies investigating postmenopausal women diagnosed with GSM, with a history of breast cancer and using hormonal therapy, were included. A meta-analysis was performed using a random-effects model, considering hazard ratios (HR) and their respective confidence intervals. Results: Of the 105 studies identified, 10 met the eligibility criteria, totaling 142,717 women. The most frequent intervention was the use of vaginal estrogen. The meta-analysis revealed a pooled HR of 0.95 (95% CI: 0.87–1.03), suggesting no significant risk for recurrence or mortality. Studies also reported improvement in GSM symptoms without elevation in serum estradiol levels. Conclusion: Evidence suggests that the use of vaginal estrogen in women with GSM and a history of breast cancer is safe when carefully indicated. Clinical decisions should consider the individual profile of each patient, promoting evidence-based interventions that enhance quality of life.
References
Valadares ALR, Kulak Junior J, Paiva LHS da C, Nasser EJ, Silva CR da, Nahas EAP, et al. Genitourinary Syndrome of Menopause. Rev Bras Ginecol Obstet [Internet]. 2022 Mar;44(3):319–24. Available from: https://doi.org/10.1055/s-0042-1748463.
Bevilacqua MRR, Costa-Paiva L, Pedro AO. Prevalence and predictors of genitourinary syndrome of menopause: a population-based study in middle-aged Brazilian women. Menopause. 2025 Feb 1;32(2):134-141. doi: https://doi.org/10.1097/GME.0000000000002467.
Beste ME, Kaunitz AM, McKinney JA, Sanchez-Ramos L. Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks. Am J Obstet Gynecol. 2025 Mar;232(3):262-270.e1. doi: https://doi.org/10.1016/j.ajog.2024.10.054.
McVicker L, Labeit AM, Coupland CAC, et al. Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol. 2024;10(1):103–108. doi: https://doi.org/10.1001/jamaoncol.2023.4508.
American College of Obstetricians and Gynecologists. Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus. Obstet Gynecol. 2021 Dec;138(6):950–60. doi: https://doi.org/10.1097/AOG.0000000000004601
Hussain I, Talaulikar VS. A systematic review of randomised clinical trials - The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors. Post Reprod Health. 2023 Dec;29(4):222-231. doi: https://doi.org/10.1177/20533691231208473.
Paraiso MFR, Ferrando CA, Sokol ER, Rardin CR, Matthews CA, Karram MM, Iglesia CB. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. Menopause. 2020 Jan;27(1):50-56. doi: https://doi.org/10.1097/GME.0000000000001416.
Hirschberg AL, Sánchez-Rovira P, Presa-Lorite J, Campos-Delgado M, Gil-Gil M, Lidbrink E, et al. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause 2020; 27: 526– 34. doi: https://doi.org/10.1097/GME.0000000000001497.
Streff A, Chu-Pilli M, Stopeck A, Chalasani P. Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors. Support Care Cancer. 2021;29(1):187–191. doi: https://doi.org/10.1007/s00520-020-05466-1.
Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JE. Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age. Am J Epidemiol. 2021 Feb 1;190(3):365-375. doi: https://doi.org/10.1093/aje/kwaa210.
Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. J Natl Cancer Inst. 2022 Oct 6;114(10):1347-1354. doi: https://doi.org/10.1093/jnci/djac112.
Mitchell CM, Larson JC, Crandall CJ, Bhasin S, LaCroix AZ, Ensrud KE, Guthrie KA, Reed SD. Association of Vaginal Estradiol Tablet With Serum Estrogen Levels in Women Who Are Postmenopausal: Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2022 Nov 1;5(11):e2241743. doi: https://doi.org/10.1001/jamanetworkopen.2022.41743.
Agrawal P, Singh SM, Able C, Dumas K, Kohn J, Kohn TP, Clifton M. Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer. Obstet Gynecol. 2023 Sep 1;142(3):660-668. doi: https://doi.org/10.1097/AOG.0000000000005294.
Sund M, Garmo H, Andersson A, Margolin S, Ahlgren J, Valachis A. Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk. Breast Cancer Res Treat. 2023 Apr;198(2):361-368. doi: https://doi.or/10.1007/s10549-023-06871-w.
Faltinová M, Vehmanen L, Lyytinen H, Savolainen-Peltonen H, Virtanen A, Haanpää M, Hämäläinen E, Tiitinen A, Mattson J. Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial. Breast Cancer Res Treat. 2025 Apr;210(2):295-305. doi: https://doi.org/10.1007/s10549-024-07564-8.
Lőczi LL, Vleskó G, Éliás M, et al. Effect of Vaginal Laser and Topical Therapies on Vulvovaginal Atrophy Symptoms in Breast Cancer Patients: A Systematic Review and Meta-Analysis. J Clin Med. 2024;13(20):6131. doi: https://doi.org/10.3390/jcm13206131.
Claes M, Tuts L, Robijns J, et al. Cancer therapy-related vaginal toxicity: its prevalence and assessment methods—a systematic review. J Cancer Surviv. 2024. doi: https://doi.org/10.1007/s11764-024-01553-y.
Benedict C, Fisher S, Kumar D, et al. Examining Associations Among Sexual Health, Unmet Care Needs, and Distress in Breast and Gynecologic Cancer Survivors. Semin Oncol Nurs. 2022;38(6):151316. doi: https://doi.org/10.1016/j.soncn.2022.151316.
Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World J Clin Oncol. 2023 Jul 24;14(7):526-544. doi: https://doi.org/10.5306/wjco.v14.i7.526.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Científica Integrada
This work is licensed under a Creative Commons Attribution 4.0 International License.
